Amgen To Buy Out Japan JV With Astellas
Full, planned acquisition of Tokyo-based operation will give US biotech giant a firmer foothold in key market and new platform for Otezla growth.
You may also be interested in...
Deal news from GeoVax/BravoVax, Onconova/HanX, Zydus Cadila/China Medical System Holdings, EyePoint/Ocumension, Ningbo NewBay Medical/Genentech, Otsuka/PhoreMost, Almirall/WuXi Biologics
Reverse merger takes Histogen public as it seeks mid-stage data for male pattern baldness by end of 2020. AstraZeneca continues divestiture spree, sending five mature hypertension drugs to Atnahs.
Amgen sees opportunity to grow Otezla sales through new indications and additional ex-US launches. The deal depends on Bristol closing its Celgene acquisition, pending FTC clearance.